Introduction
Accumulation of macrophage foam cells is a hallmark of atherosclerosis. The intracellular free cholesterol level is increased by the uptake of oxidized low-density lipoprotein (oxLDL) via scavenger receptors, and is decreased by the efflux of free cholesterol mediated by ATP-binding cassette transporter A1 (ABCA1) ( 1 ) . As excessive accumulation of free cholesterol is toxic to cells, free cholesterol must be either removed through efflux to extracellular acceptors, such as apolipoprotein A1 and high-density lipoprotein (HDL), or esterified to cholesterol ester (CE) by the microsomal enzyme acyl-CoA:cholesterol acyltransferase-1 (ACAT1) ( 2 ) . How-ever, massive accumulation of CE lipid droplets by ACAT1 in macrophages (foam cell formation) is a key event in the development of atherosclerosis ( 2 ) . ACAT1 has been regarded as a target molecule of pharmacological intervention for preventing atherosclerosis and related complications ( 3 ) .
Angiotensin II (Ang II), an octapeptide vasoconstrictor produced by the renin-angiotensin system, is implicated in hypertension and atherosclerosis ( 4 ) , and has been identified in human macrophages in coronary atherosclerotic lesions ( 5 ) . Infusion of Ang II into atherogenic apoE or LDL receptor deficient mice significantly increases macrophage-driven atherosclerotic lesions ( 6 , 7 ) . Ang II stimulates monocyte migration, macrophage-mediated LDL oxidation, macrophage cholesterol biosynthesis, and oxLDL uptake, and decreases HDL-induced cholesterol efflux from macrophages ( 7 -9 ) .
Ang II type 1 (AT 1 ) and type 2 (AT 2 ) receptors, members of the G-protein-coupled receptor (GPCR) superfamily, are expressed in human monocyte-macrophages ( 10 ) as well as in vascular smooth muscle cells (VSMCs), endothelial cells, and fibloblasts. Most of the proatherogenic effects of Ang II are mediated via the AT 1 receptor ( 11 ), whereas the monocyte matrix metalloproteinase-1 is upregulated via the AT 2 receptor ( 12 ) . However, little is known about the effect of Ang II on ACAT1 expression, as a molecular and cellular mechanism of foam cell formation, particularly in primary human monocyte-macrophages.
Therefore, in the present study, we assessed the effects of Ang II on foam cell formation and ACAT1 expression and the role of AT 1 and AT 2 receptors in Ang II-induced ACAT1 expression in primary human monocyte-macrophages. We investigated the post-receptor intracellular signal transduction pathways of Ang II-induced ACAT1 expression in human monocyte-macrophages.
Methods
This study was approved by the Ethics Committee of Showa University. Blood was collected from male healthy volunteers who were free from hypertension, diabetes, dyslipidemia, or ischemic heart disease, and were taking no medications.
Chemicals
Human Ang II, L162313, CGP42112A, [Sar 1 ,Ile 8 ]-Ang II, PD123319, GDP-β -S, PP2, rottlerin, PD98059, AG490, and anti-β -actin antibodies were purchased from Sigma (St. Louis, USA). Anti-SR-A and anti-ABCA1 antibodies were obtained from R&D Systems (Minneapolis, USA) and the anti-CD68 antibody was from Santa Cruz Biotechnology (Santa Cruz, USA). Candesartan was a gift from Takeda Pharmaceutical Co., Ltd. (Osaka, Japan). Anti-human ACAT1 antibody (DM10) was donated by the Department of Biochemistry, Dartmouth Medical School (Hanover, USA).
Cell Culture
Human peripheral mononuclear cells were isolated from the blood by Ficoll density gradient centrifugation (13) (14) (15) . Purified monocytes were suspended in RPMI1640 medium and seeded onto 6-cm dishes (4 × 10 6 cells/dish) for immunoblot analysis, 10-cm dishes (2 × 10 7 cells/dish) for an ACAT activity assay and Northern blot analysis, and 3.5-cm dishes (1 × 10 6 cells/dish) for CE assay. After 1 h of incubation for adherence, the medium was replaced with RPMI1640 medium supplemented with 10% pooled human sera.
Adherent monocytes were incubated at 37°C in 5% CO2 for 7 d to induce differentiation into macrophages in the presence or absence of the indicated concentrations of Ang II, an AT1 receptor agonist (L162313), or an AT2 receptor agonist (CGP42112A). The medium was replaced every 3 d (on day 3 and day 6) with fresh medium and medium replacement was followed by the addition of Ang II, the AT1 agonist, or the AT2 agonist. For antagonist experiments, the AT1 receptor antagonist (candesartan or [Sar 1 ,Ile 8 ]-Ang II) or the AT2 receptor antagonist (PD123319) was added 1 h before the addition of Ang II. To evaluate the post-receptor intracellular signal transduction pathways of Ang II-induced ACAT1 expression, inhibitors of G-proteins (GDP-β-S), c-Src tyrosine kinase (PP2), protein kinase C (PKC) (rottlerin), mitogen activated protein kinase (MAPK) kinase (PD98059), or Jak2 (AG490) were added along with Ang II.
To ensure that the blocking activities of the antagonists or inhibitors were not due to their cytotoxic effects, doseresponse studies were performed with only the antagonists or inhibitors to identify a concentration that is neither cytotoxic nor disturbs monocytic differentiation into macrophages.
Immunoblot Analysis
Cell extracts (25 μg of protein) were separated by 10% SDSpolyacrylamide gel electrophoresis and subjected to Western blotting with antibodies against human ACAT1, ABCA1, SR-A, or CD68 (13) (14) (15) .
ACAT Enzyme Activity
Cell extracts (80 μg) were incubated for 30 min at 37°C with 20 μL of 250 μmol/L [ 14 C]oleoyl-CoA followed by determination of cholesterol [
14 C]oleate (13) (14) (15) .
Northern Blot Analysis
Total RNA was extracted from cultured cells and electrophoresed on 1% agarose gels containing 2.2 mol/L formaldehyde followed by Northern blotting for ACAT1 mRNA (13, 15) .
Assays for Intracellular CE Accumulation
Human LDL (d= 1.019-1.063) and acetylated LDL (acLDL) were prepared as described previously (13 (13, 14) . Aliquots (0.75 mL) of the culture medium were mixed with 0.25 mL of 40% trichloroacetic acid. To this solution, 0.2 mL of 0.7 mol/L AgNO3 was added, and the resulting solution was centrifuged at 2,500 rpm for 10 min. Trichloroacetic acid-soluble radioactivity in the supernatant and cell-associated radioactivity were determined as previously described (13, 14) .
Statistical Analysis
Data expressed as mean±SEM were compared by Student's unpaired t-test between two groups and by ANOVA followed by Bonferroni's post hoc test when > 2 groups were examined. A p-value < 0.05 was considered significant.
Results

Time-Dependent Effect of Ang II on ACAT1 Expression in Human Monocyte-Macrophages
The expression of ACAT1 protein during differentiation from monocytes into mature macrophages in the presence or absence of exogenous Ang II was determined by immunoblot analysis. At the same time, the levels of Ang II endogenously produced by cultured monocyte-macrophages were determined by radioimmunoassay (Ang II RIA kit; SRL, Inc., Tokyo, Japan). In the absence of exogenous Ang II, ACAT1 expression increased significantly, in a time-dependent manner, during monocytic differentiation into macrophages, and reached the maximal level on day 7 (Fig. 1A) . Under these conditions, Ang II concentrations in the culture medium were 7.0±3.0 pmol/L on day 0, 11.2±2.2 pmol/L on day 3, and 10.2±3.1 pmol/L on day 7; there were no significant differences among these concentrations. The concentrations of Ang II produced endogenously by monocyte-macrophages during culture were minor in comparison to the concentration of Ang II added exogenously. During monocytic differentiation into macrophages without exogenous Ang II, treatment with candesartan (10 μmol/L), an AT1 receptor-selective antagonist, or PD123319 (10 μmol/L), an AT2 receptor-selective antagonist, did not affect ACAT1 protein expression (0.98±0.07 and 1.00±0.05 fold of the control). In the presence of exogenous Ang II, the expression of ACAT1 was significantly enhanced compared with expression in the absence of Ang II on days 5 and 7 (Fig. 1A) . Figure 1B shows the concentration-dependent effect of Ang II on ACAT1 protein expression in human monocyte-macrophages on day 7. Ang II significantly increased ACAT1 expression in a concentration-dependent manner. A maximal increase in ACAT1 expression of two-fold was observed at 1 μmol/L.
Dose-Dependent Effect of Ang II on ACAT1 Expression in Human Monocyte-Macrophages
Effect of AT1 or AT2 Receptor Agonists on ACAT1 Expression in Human Monocyte-Macrophages
We assessed the concentration-dependent effect of agonists of the AT1 receptor (L162313) and the AT2 receptor (CGP42112A) on ACAT1 protein expression in monocytemacrophages on day 7. L162313 increased ACAT1 protein expression in a concentration-dependent manner, with a maximal increase of 1.8-fold observed at 1 μmol/L (Fig. 2A) . In contrast, CGP42112A did not have a statistically significant effect on ACAT1 expression at any of the concentrations tested (Fig. 2B ). Figure 3A shows the concentration-dependent effect of Ang II on ACAT activity in human monocyte-macrophages on day 7. Ang II significantly increased ACAT activity in a concentration-dependent manner, with a maximal increase of twofold observed at 1 μmol/L. The increase in ACAT activity paralleled the increase in ACAT1 protein expression. 
Dose-Dependent Effect of Ang II on ACAT Activity in Human Monocyte-Macrophages
Effect of Ang II on ACAT1 mRNA Levels in Human Monocyte-Macrophages
Densitometric scanning of Northern blots of monocyte-macrophages on day 7 revealed that Ang II significantly increased the levels of the 2.8-and 3.6-kb transcripts by 1.6-fold and 1.4-fold, but had no significant effect on the 4.3-or 7.0-kb transcripts (Fig. 4A, B) .
Intracellular Signal Transduction of Ang IIInduced ACAT1 Expression in Human MonocyteMacrophages
We assessed the effects of inhibitors of G proteins (GDP-β- 
Effects of Ang II on Differentiation Markers and Endocytosis of acLDL in Human Macrophages
Incubation of monocyte-macrophages with Ang II (1 μmol/L) for 7 d did not significantly alter the protein expression of ABCA1, SR-A, or CD68 as differentiation markers (Fig. 5A) . Figure 5B and C show the effects of Ang II on the endocytosis of acLDL as SR-A function in human macrophages. Neither the cell association nor endocytic degradation of [ 125 I]acLDL was significantly affected by Ang II (1 μmol/L).
Effect of Ang II on Intracellular CE Accumulation in Human Macrophages
The effect of Ang II on cholesterol [ 3 H]oleate accumulation in human macrophages was observed at 5 μg/mL of acLDL more clearly than at higher concentrations in our preliminary experiments (data not shown). As shown in Fig. 6A 
Discussion
The present study demonstrates that Ang II accelerated foam cell formation by upregulating ACAT1 expression predominantly through the AT1 receptor followed by the G protein/cSrc/PKC/MAPK pathway in primary human monocyte-macrophages. To our knowledge, our study provides the first evidence that treatment with an AT1 receptor blocker (ARB) can suppress Ang II-enhanced ACAT1 expression and foam cell formation in human monocyte-macrophages, contributing to the prevention of atherosclerosis. Human monocytes express AT1 receptors at higher levels than AT2 receptors (17) . Expression of both receptors increases during differentiation of human monocytes into macrophages (10) . AT1 receptor expression in the vasculature is increased by oxLDL, high glucose, and inflammatory cytokines, such as interleukin-6 and C-reactive protein (18) . The expression levels of the AT1 receptor define the biological efficacy of Ang II. Deletion of the AT1 receptor in apoE-deficient mice results in attenuated atherosclerotic lesions (19) . ARB has been widely used as an antihypertensive drug with the expectation of anti-atherosclerotic effects. Previous studies have shown that ARB decreases oxidative stress and LDL oxidation in the vessel wall and reduces the development of atherosclerosis (20) . In addition, ARB has been shown to reduce plaque size by attenuating macrophage infiltration and VSMC proliferation in the aorta of diabetic apoE-deficient mice. Johnstone et al. (21) showed that candesartan reduces macrophage accumulation within the plaque but increases collagen deposition, contributing to plaque stabilization. Koga et al. (22) reported that inflammatory mechanisms are involved in the development of atherosclerosis based on their data that a blockade of the interferon-γ receptor can suppress atherosclerotic lesions in apoE-deficient mice. An ARB that acts as a peroxisome proliferators-activated receptor-γ agonist shows anti-inflammatory effects (23, 24) . ARB ameliorates inflammatory changes by decreasing both monocyte chemoattractant protein-1 expression and macrophage infiltration in glomeruli in patients with hypertensive nephrosclerosis (25) . Deletion of ACAT1 brought destabilization of cellular membrane function on cholesterol accumulation and cell death in macrophages from ACAT1-deficient mice (26) . In contrast, partial ACAT inhibition in vivo by an ACAT1-selective inhibitor suppressed atherosclerosis without cytotoxicity to macrophages (27) . Moreover, adverse effects have not been reported in recent clinical trials of ACAT inhibitors (28) . Inhibition of Ang II-induced ACAT1 expression by candesartan may not produce unfavorable effects on macrophages in vivo.
Fig. 3. A: Effects of Ang II on ACAT activity in human monocyte-macrophages. B: Effects of an AT1 or AT2 receptor-selective antagonist on Ang II-induced ACAT1 protein expression (top) and ACAT activity (bottom) in human mono
In primary human monocyte-macrophages, ACAT1 is upregulated by urotensin II, serotonin, salusin-β, and transforming growth factor-β1 (TGF-β1) and is downregulated by salusin-α and adiponectin (13-15, 29, 30) . Ang II significantly increases ACAT1 expression, but not ABCA1, SR-A, and CD68, which are known to increase during monocytemacrophage differentiation (14) . These findings suggest that ACAT1 upregulation by Ang II is independent of cell differentiation.
The human ACAT1 gene encodes four different mRNA species of 2.8, 3.6, 4.2, and 7.0 kb. These four transcripts contain a full-length ACAT1 open reading frame and various sizes of untranslated regions, including different promoters. It is possible that all four transcripts produce ACAT1 protein. In general, the major transcripts (2.8 and 3.6 kb) are regarded as quantitatively important players for ACAT1 transcription. However, the exact contribution of each transcript to ACAT1 translation is unknown. We demonstrated increases in two of these transcripts (2.8 and 3.6 kb) in response to Ang II in the present study as well as other vasoactive agents and TGF-β1 in the previous studies (13, 15, 29) . In our previous studies, the effects of Ang II on VSMC proliferation and hypertrophy were shown to be mediated by AT1 receptors followed by various intracellular signal transduction mechanisms, such as Gq, tyrosine kinases, PKC, and MAPK. In addition to the MAPK pathway, Ang II activates the Jak2/STAT3 pathway via AT1 receptors (11) . In the present study, we examined the pathways of ACAT1 expression that are stimulated by Ang II in human monocyte-macrophages. Ang II-induced ACAT1 upregulation was completely abolished by G protein, c-Src, PKC, or MAPK kinase inhibitors, but partially inhibited by a Jak2 inhibitor. These observations suggested that the G protein/c-Src/PKC/ MAPK pathway is mainly involved in Ang II-induced ACAT1 upregulation in human monocyte-macrophages. Similarly, this signal transduction pathway participates in ACAT1 expression enhanced by other GPCR agonists, such as urotensin II and serotonin (13, 15) .
The concentration of Ang II necessary for ACAT1 stimulation was relatively high compared with physiological plasma levels of Ang II in humans. Our previous studies demonstrated that Ang II within the same range of concentrations significantly induced VSMC proliferation via the AT1 receptor (11, 31) . Several animal studies have shown that release of Ang II from cardiomyocytes in response to mechanical stretch reaches 100-fold over baseline in vitro (32) , and Ang II concentrations in interstitial fluid from the heart or the kidney are 100-or 1,000-fold higher, respectively, than in plasma (33) . In human atherosclerotic lesions, a large amount of Ang II is generated locally by angiotensin-converting enzyme and chymase in the autocrine/paracrine manner (34, 35) . It is possible that Ang II concentrations around monocyte-macrophages within atherosclerotic lesions may reach those required for ACAT1 stimulation. This phenomenon requires further investigation in vivo to assess its clinical relevance. Expression of both the AT1 and AT2 receptors increased during differentiation of THP1 monocytes into macrophages in the absence of exogenous Ang II (10) . In the presence of exogenous Ang II, AT1 and AT2 receptors are downregulated in THP1-derived macrophages (10) . However, changes in AT1 or AT2 receptor expression during differentiation of primary cultured human monocytes into macrophages in the presence of exogenous Ang II have not been elucidated. Further studies are needed to clarify the role of the expression of AT1 and AT2 receptors in human monocyte-macrophage culture system used in the present study.
In conclusion, Ang II enhances foam cell formation by upregulating ACAT1 expression predominantly via the AT1 receptor acting through the G protein/c-Src/PKC/MAPK pathway in human monocyte-macrophages. These findings provide an understanding of potential molecular mechanisms by which hypertension promotes the development of atherosclerosis. Our study suggests that ARB against monocyte- 
